Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Dornbusch, Juana ^a   Zacharis, Aristeidis ^a   Meinhardt, Matthias ^a   Erdmann, Kati ^a   Wolff, Ingmar ^a   Froehner, Michael ^a   Wirth, Manfred P ^a   Zastrow, Stefan ^a   Fuessel, Susanne ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; CD34 ANTIGEN; GENOMIC DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GENE DOSAGE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL PREDICTION; TISSUE MICROARRAY; TUMOR VASCULARIZATION; VHL GENE;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD31; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDOLES; KI-67 ANTIGEN; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84884680394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076386     Document Type: Article

References (64)

1. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF, (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44: 65-75.
2. Malaguarnera M, Ferlito L, Gulizia G, Di Fazio I, Pistone G, (2001) Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur J Clin Pharmacol 57: 267-273.
3. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. Jama 295: 2516-2524.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
5. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
6. Young AC, Craven RA, Cohen D, Taylor C, Booth C, et al. (2009) Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res 15: 7582-7592.
7. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, et al. (2009) Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 101: 1417-1424.
8. Matsuda D, Khoo SK, Massie A, Iwamura M, Chen J, et al. (2008) Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett 272: 260-267.
9. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011.
10. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
11. Kim WY, Kaelin WG, (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004.
12. Ferrara N, (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814.
13. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, et al. (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811.
14. Muriel Lopez C, Esteban E, Astudillo A, Pardo P, Berros JP, et al. (2012) Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 30: 2443-2449.
15. Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, et al. (2003) Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Am J Pathol 163: 1013-1020.
16. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, et al. (2007) Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol 28: 158-164.
17. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, et al. (2007) Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 131: 261-267.
18. Liang YX, He HC, Han ZD, Bi XC, Dai QS, et al. (2009) CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 27: 788-793.
19. Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y, (2010) Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 344: 23-31.
20. Patel PH, Chadalavada RS, Ishill NM, Patil S, Reuter VE, et al. (2008) Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 26: abstract 5008.
21. Terakawa T, Miyake H, Kusuda Y, Fujisawa M (2011) Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol.
22. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, et al. (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773.
23. Li XS, Wu X, Zhao PJ, Huang LH, Song Y, et al. (2011) Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin Med J (Engl) 124: 2920-2924.
24. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M, (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85: 357-368.
25. Geretti E, Klagsbrun M, (2007) Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr 1: 56-61.
26. Harper SJ, Bates DO, (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887.
27. Biswas S, Charlesworth PJ, Turner GD, Leek R, Thamboo PT, et al. (2012) CD31 angiogenesis and combined expression of HIF-1alpha and HIF-2alpha are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFalpha transcriptional products are not: implications for antiangiogenic trials and HIFalpha biomarker studies in primary CC-RCC. Carcinogenesis 33: 1717-1725.
28. Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, et al. (2013) Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med 11: 15.
29. Wang P, Zhen H, Zhang J, Zhang W, Zhang R, et al. (2012) Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog 51: 586-595.
30. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, et al. (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60: 644-661.
31. Laird A, O'Mahony FC, Nanda J, Riddick AC, O'Donnell M, et al. (2013) Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One 8: e60483.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
33. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, et al. (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123: 395-400.
34. Sauter G, Simon R, Hillan K, (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov 2: 962-972.
35. Buchner A, Riesenberg R, Kotter I, Hofstetter A, Stief C, et al. (2006) Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma. Cancer 106: 1514-1520.
36. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, et al. (2010) Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 5: e10715.
37. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, et al. (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180: 860-865 discussion 865-866.
38. Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, et al. (2011) Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 35: 1549-1556.
39. Byun SS, Yeo WG, Lee SE, Lee E, (2007) Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 69: 34-37.
40. Yilmazer D, Han U, Onal B, (2007) A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma. Int Urol Nephrol 39: 691-698.
41. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, et al. (2004) Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171: 2461-2466.
42. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, et al. (2009) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 105: 1247-1254.
43. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, et al. (2012) Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int 109: 1349-1354.
44. Bono P, Rautiola J, Utriainen T, Joensuu H, (2011) Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50: 569-573.
45. Michaelson MD, Cohen DP, Li S, Motzer RJ, Escudier B, et al. (2011) Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). J Clin Oncol 29: abstract 320.
46. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337.
47. Choueiri TK, Regan MM, Brick AJ, Clement JM, Kwabi C, et al. (2008) Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy J Clin Oncol 26: abstract 16042.
48. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, et al. (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748.
49. Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, et al. (2012) C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 19: 908-913.
50. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, et al. (2012) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23: 46-52.
51. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, et al. (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17: 620-629.
52. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, et al. (2012) Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118: 1946-1954.
53. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
54. Sakai I, Miyake H, Fujisawa M, (2013) Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int 112: E211-220.
55. Rini BI, (2010) New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16: 1348-1354.
56. Pénzválto Z, Tegze B, Szász AM, Sztupinszki Z, Likó I, et al. (2013) Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One 8: e59503.
57. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, et al. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94: 1569-1575.
58. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, et al. (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98: 756-762.
59. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, et al. (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961.
60. Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, et al. (2011) VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin. Cell Oncol (Dordr) 34: 225-234.
61. Escudier B, Albiges L, Massard C, Loriot Y, Fizazi K, (2012) How to select amongst available options for the treatment of advanced RCC? Ann Oncol 23Suppl 10: x309-312.
62. Escudier B, Porta C, Bono P, De Giorgi U, Parikh O, et al. (2012) Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 30: abstr CRA4502.
63. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
64. Grünwald V, Merseburger AS, (2012) Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther 5: 111-117.